{"grounding": "Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger, mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is one of the 11 members of the cyclic nucleotide phosphodiesterase (PDE) family that specifically targets cGMP generated by nitric oxide\u2013driven activation of the soluble guanylyl cyclase. PDE5 inhibitors, including sildenafil and tadalafil, are widely used for the treatment of erectile dysfunction, pulmonary arterial hypertension, and certain urological disorders. Preclinical studies have shown promising effects of PDE5 inhibitors in the treatment of myocardial infarction, cardiac hypertrophy, heart failure, cancer and anticancer-drug-associated cardiotoxicity, diabetes, Duchenne muscular dystrophy, Alzheimer's disease, and other aging-related conditions. Many clinical trials with PDE5 inhibitors have focused on the potential cardiovascular, anticancer, and neurological benefits. In this review, we provide an overview of the current state of knowledge on PDE5 inhibitors and their potential therapeutic indications for various clinical disorders beyond erectile dysfunction.", "generated_text": "cGMP-specific phosphodiesterase 5 (PDE5) inhibitors, primarily recognized for their role in treating erectile dysfunction, have emerged as promising therapeutic agents for a variety of other clinical disorders. This review explores the expanding applications of PDE5 inhibitors beyond their traditional use, focusing on their potential in addressing endothelial dysfunction, providing cardioprotection, and managing metabolic disorders. The mechanisms by which PDE5 inhibitors exert beneficial effects in these conditions are linked to their ability to enhance nitric oxide signaling, improve vascular function, and modulate inflammatory pathways. Additionally, emerging evidence suggests their role in mitigating age-related pathologies and offering therapeutic benefits in certain cancer types. By examining current research and clinical trials, this paper highlights the multifaceted potential of PDE5 inhibitors, advocating for further investigation into their broader clinical applications and the development of novel therapeutic strategies targeting these pathways.", "label": 1}